PTX 2.44% 4.2¢ prescient therapeutics limited

Ann: Encouraging Pre-Clinical Data Presented at US Cancer Meeting, page-2

  1. 2,863 Posts.
    lightbulb Created with Sketch. 26
    PTX-100 reduced multiple myeloma tumours AND sensitised multiple myeloma cells in mice models.

    Should see buyers return to the stock as the data is presented today at the Cancer Research Meeting.

    EV value of $2M is absurd given the trials both pending and underway.

    Even at 16c the stock would still be cheap compared to its ASX peers.

    Cheers.

    .
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.